Back to Journals » Clinical and Experimental Gastroenterology » Volume 11

Retrospective analysis of a lactose breath test in a gastrointestinal symptomatic population of Northeast Italy: use of (H2+2CH4) versus H2 threshold

Authors Peron G, Dall'Acqua S , Sorrenti V , Carrara M , Fortinguerra S , Zorzi G , Buriani A 

Received 28 January 2018

Accepted for publication 8 March 2018

Published 18 June 2018 Volume 2018:11 Pages 243—248

DOI https://doi.org/10.2147/CEG.S163962

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Prof. Dr. Everson L.A. Artifon



Gregorio Peron,1 Stefano Dall’Acqua,1,2 Vincenzo Sorrenti,1,3 Maria Carrara,1 Stefano Fortinguerra,3 Giulia Zorzi,3 Alessandro Buriani3

1
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy; 2Unir&d, Nutraceutical Laboratory, Padova, Italy; 3Maria Paola Belloni Center for Personalized Medicine, Data Medica Group, Synlab Limited, Padova, Italy

Background: Lactose malabsorption is normally evaluated by measuring exhaled H2 produced by intestinal flora, from unabsorbed lactose. However, differing microbiome composition can lead to the production of CH4 instead of H2; hence, some authors challenge the H2 method sensitivity and favor the evaluation of both intestinal gases.
Aim: To compare different approaches to usage of a lactose breath test for lactose malabsorption diagnosis, after medical evaluation of gastrointestinal symptoms.
Methods: In a retrospective observational study, we compared the 2 approaches in a population of 282 subjects in Northern Italy. Following oral lactose administration, exhaled samples were harvested every 30 minutes for 4 hours and prepared for H2 and CH4 analysis. Basal gas levels were subtracted from H2 and CH4 ppm and values at 4 hours and peaks were considered for analysis.
Results:
Applying the standard methodology, which takes separately into consideration H2 and CH4 produced in the intestinal lumen, the results indicated that 11.7% of the patients were diagnosed “positive” for hypolactasia, differently from what was expected. Conversely, taking into consideration the sum of H2 and CH4, the percentage increased to 62.8%, closer to the expected one. No significant differences were found when comparing the 2 groups for age, gender, or symptoms. The sizable difference between the 2 approaches is likely linked to gut microbiome variability, and consequently the different production of the 2 gases, in the population.
Conclusion: The threshold normally used for lactose breath test should be reconsidered and changed, merging H2 and CH4 stoichiometric values to increase sensitivity.

Keywords: lactose malabsorption, intestinal malabsorption, hypolactasia, H2+2CH4 threshold

Introduction

Primary lactose intolerance is a widely diffused gastrointestinal disorder in which the organism cannot completely digest the sugar present in milk and its derivatives, leading to symptoms such as flatulence, meteorism, diarrhea, intestinal pain, and abdominal cramps.13 In particular, lactose intolerance is the most common form of carbohydrate malabsorption and affects people of all ages.46 The cause of this malabsorption is due to the deficiency of lactase, an enzyme that is normally present in the small intestine. Under normal conditions, after ingestion, lactose is hydrolyzed by lactase in the intestine (the highest activity of this enzyme is in jejunum) to form glucose and galactose. The 2 monosaccharides are then actively absorbed by the intestinal mucosa. In case of lactase deficiency, lactose reaches the colon where it is fermented by the bacterial flora to produce various gases, including hydrogen (H2) and methane (CH4). These, in part, are absorbed and subsequently eliminated through the lungs.7,8 Given that the human organism does not produce either H2 or CH4, when administering lactose in controlled conditions to lactase-deficient patients, the amount of gases measured in the subject’s breath is considered a measure of the unabsorbed sugar. These “Breath Tests,” after lactose challenge, are considered a standard diagnostic approach to identify lactase deficiency.712 Lactose malabsorption is diagnosed when breath test values are above a specific threshold value of either H2 or CH4, or both.9,10,13 A consensus conference back in 2009 had suggested a standardization of the analytical method to be used for lactose breath tests, with a focus mainly on H2 intestinal production and a relatively high threshold value for positives, thus privileging specificity over sensitivity.14 During the consensus conference, the issue of intestinal variability of H2/CH4-producing flora was not taken into account.14 The 2017 North American consensus conference did not add much to the specific issue, confirming the guidelines.13 Nevertheless, a limited sensitivity can lead to missing or delaying lactate malabsorption diagnosis. Some authors have questioned the Rome guidelines and propose to increase the sensitivity of the assay, promoting analytical approaches that take into consideration equally the production of both gases and the high variability of the subject’s intestinal microbiome, with an unpredictable proportion of H2-producing microbes, versus CH4-producing ones.15,16 The aim of the present study was to compare different analytical approaches of the same lactose breath test in a retrospective study of patients prescribed the test after medical evaluation of gastrointestinal symptoms for a suspected lactose malabsorption condition.

The genetic variability of intestinal lactase is responsible for lactase persistency in the adult and is extremely variable in the general population, ranging from almost 0 in some Asian Countries to high levels found in Northern Europe.4,5,9,17,18 The lack of lactase persistency is considered responsible for lactose malabsorption. Recently published studies took showed the incidence of lactose malabsorption among Italian population to be 72%.19 Another study recently published by Zadro et al20 investigated the frequency of lactase nonpersistence genotype among Italian population. The results showed 62.3% of lactase nonpersistence genotype, with no significant differences among 3 macroregions of the country (58.6%, 74.1%, and 67.1% detected in North, Center, and South, respectively).

Our study is, to date, the first lactose breath test study conducted in North East Italy on a population of patients suspected of lactose malabsorption.

Materials and methods

Subjects and sample collection

Diagnostic data were retrospectively collected, pooled, and analyzed from lactose breath tests of outpatient subjects referring to a community-based laboratory facility in the Veneto Region in Northeast Italy, Data Medica Padova, from January 2014 to June 2016. The facility was part of a group of private health care providers operating under agreement with the public health care system to deliver healthcare to the public. The center was also ISO9001 certified and accredited for excellence in health care services by Accreditation Canada International. The retrospective observational study was carried out according to Good Practice in Clinical Research, approved by the Data Medica Group Scientific Technical Committee, and, following national Italian legislation, approved by the local reference Ethics Committee for Clinical Trials of the Province of Padua (DM 2016/01). All study participants provided informed written consent prior to study enrollment.

The analysis involved 282 subjects whose breath tests results were obtained from the laboratory database and rendered anonymous before elaboration. For each patient, age, sex, self-declared reason for taking the exam (grouped into “intestinal pain,” “meteorism,” “nausea,” “diarrhea,” “no symptoms specified”), and breath test diagnostic outcome were collected. H2 values at 4 hours and H2 and CH4 peak values were also considered for further analysis.

Breath test

Before the test, patients had to fast and follow a series of dietary, pharmacological, and behavioral prescriptions, as indicated by the manufacturer, and on the day of the assay they were asked to fill a questionnaire with identification data and the reasons for the examination. EXPIROlact® H2 Breath Test Kit for the determination of lactose intolerance (Sofar SpA, Milan, Italy) was used for the assay, and a standard procedure furnished by the kit manufacturer was followed. Briefly, following the oral administration of 25 g of lactose suspended in 150 mL of tap water, exhaled samples were harvested every 30 minutes for 4 hours and prepared for H2 and CH4 analysis.10 Basal gas levels were subtracted from H2 and CH4 ppm, and values at 4 hours and peaks were considered for analysis. No sample had peaks of H2 values above 20 ppm within 1.5 hours from lactose ingestion, which would have suggested small intestinal bacterial overgrowth13 and would have been eliminated from the study.

The analysis was conducted with a Quintron microlizer BreathTracker Analyzer (QuinTron Instrument Company, Inc., Milwaukee, WI, USA), based on solid-state sensors.

Statistical analysis

Statistic analyses were performed using GraphPad Prism (v 5.01; Graphpad Inc., La Jolla, CA, USA). Statistical comparisons for subgroups were computed using 1-way analysis of variance followed by post hoc tests for selected comparisons or 2-tailed Student’s t-test.

Results

A retrospective analysis was performed on a sample of 282 patients who underwent a lactose breath test between 2014 and 2015 in an outpatient laboratory in Northern Italy. Patients with a diagnosis of major gastrointestinal diseases were excluded from this study. Mean age was 35 years, and females were twice the number of males enrolled in the study. Most patients were sent for the test by a general practitioner or a specialist, with suspected hypolactasia potentially linked to 1 or more gastrointestinal symptoms as declared initially by the patients themselves (Table 1 provides a sample description). None of the samples considered for the present study had unacceptable baseline values (≥20 ppm). Two protocols were followed to determine lactose malabsorption. One is based on the maximum ppm values at 4 hours following lactose challenge of either H2 or CH4 (Threshold >20 ppm), and is the method ordinarily used.2,10 The second approach took into consideration the stoichiometric sum of the ppm values of both H2 and CH4 (H2+2CH4) (Threshold >18 ppm) in the same time frame following lactose oral administration.4,10,15 Since in some cases peak values did not correspond to those determined at 4 hours, we further collected those values for comparison.

Table 1 Characteristics of the subjects enrolled in the study

Note: aData presented as mean ± SD.

As shown in Table 2 and Figure 1, the percentage of positive samples using the first method was 11.4%, with an average value of H2 at 4 hours of 11.34 ppm. When using the stoichiometric sum of H2 and CH4, the number of positives dramatically increases up to 62.8%. Ppm values obtained using the peak values were clearly higher, although nonsignificantly (p-value >0.05). Nevertheless in the latter case the number of positive subjects increased, more so when using the second method, a difference leading to a significant diagnostic impact.

Figure 1 Histogram reporting the percentages of patients who showed “positive” results to the breath test analysis.

Notes: Comparisons were performed between measurements of H2 and H2+2(CH4), monitored at 4 hours after lactose challenge and at Cmax.

Abbreviation: Cmax, peak concentration.

Table 2 Breath test results

Notes: aThreshold >20 ppm; bthreshold >18 ppm. Data presented as mean ± SD unless otherwise stated.

Abbreviation: Cmax, peak concentration.

Relevant differences are thus seen between the different analytical approaches, while the same qualitative differences were found when comparing the positive samples from different subgroups of patients (Tables 35). When considering 5 different age ranges, all the analytical approaches show the same trends, with a higher value below 20 years, which lowers and increases again reaching top ppm values when considering the higher age range (Table 3). No differences were seen between male and females in all methods (Table 4), and the same distribution was also seen for symptomatology among methods (Tables 5 and 6), with no subgroup significantly higher than the others within each method (p-value >0.05). Hence, results suggest that the different methods have only a difference in sensitivity, and do not differ in qualitative terms.

Table 3 % of positives and mean ppm values among different age groups

Notes: aThreshold >20 ppm; bthreshold >18 ppm.

Abbreviation: Cmax, peak concentration.

Table 4 % of positives and mean ppm values between the sexes

Notes: aThreshold >20 ppm; bthreshold >18 ppm.

Abbreviation: Cmax, peak concentration.

Table 5 % of positives and mean ppm values among patients grouped by common symptoms (H2 test results)

Note: Data presented as mean ± SD unless otherwise stated.

Abbreviation: Cmax, peak concentration.

Table 6 % of positives and mean ppm values among patients grouped by common symptoms (H2+2CH4 test results)

Note: Data presented as mean ± SD unless otherwise stated.

Abbreviation: Cmax, peak concentration.

Discussion

The present retrospective observational study was meant to give a contribution to the discussion on the diagnostic application of lactose breath test. In particular, the aim of the study was to establish the frequency of positive lactose breath tests in a group of patients affected by gastrointestinal symptoms who took the test in a local outpatient ambulatory center in Northeastern Italy. Results unexpectedly indicated a rather low frequency of positive tests when the standard analytical methodology was used.9 The same results were thus reevaluated using a different approach used by some other authors,15 which was characterized by a higher sensitivity and the same level of precision.15 This approach led to a much higher proportion of positive samples, as one would have expected in a population of gastrointestinal patients suspected of lactose intolerance. Lactase deficiency is considered a rather frequent condition, though it is known that it is highly variable in the general population and dependent on race and latitude,4,18 making it difficult to establish fixed rules for diagnostic appropriateness without a precise figure of what to expect in a given geographical area. Recent studies have been conducted on the Italian local population, showing no significant variations in the frequency of lactase nonpersistence genotype among 3 macro-areas of the country.20 The values of the frequency of this genetic condition affecting lactose absorption are expected to fall in the range of 60%–70%, according to the studies of Storhaug et al19 and Zadro et al.20 When we applied the standard analytical methodology, which takes into consideration H2 and CH4 produced in the intestinal lumen separately, we identified only 11.7% of the patients as positive for the lactose breath test, a figure rather different from what was expected. When we changed the analytical approach, taking into consideration the sum of the 2 bacterial gases produced from lactose by the intestinal flora, the result changed and approached closer to the expected one (62.8%).

When lactose reaches the intestinal lumen, the first bacterial population encountered produces H2 as an end product. If lactose escapes this first level, it can be metabolized by a different microbial population, producing CH4 as metabolic end product.15 As a consequence, these 2 molecules together, and not separately, account for the total amount of lactose that is not absorbed. When considering them singularly, 2 problems could arise: first of all, variability in the results linked to variability of microbiome in different patients. A second issue is linked to low sensitivity, potentially leading to the identification of a lower amount of lactose malabsorption cases, with important consequences on patients’ health and therapeutic options. Conversely, the sum of the 2 molecules, stoichiometrically corrected (since the hydrogen produced from lactose is twice as much as the amount of CH4), is not dependent on the microbiome variability, since it includes both types of microbial populations. The first consensus meeting on the subject in 2009 recommended the use of either H2 or CH4 to determine positivity to the lactose breath test,14 but since then others have challenged the decision, while the 2017 consensus did not touch upon the issue.13 In particular, our results indicate that the 2 analytical approaches yield 2 different diagnostic outcomes. While the quantitative difference between the 2 tests is very high, the 2 methods do not seem to carry qualitative differences, at least in the parameters considered in the present retrospective study. Considering different age groups, the frequency trends are similar, and there are no significant differences in the sex stratification of the positive samples. Similarly, we could not find significant differences in the stratification of the groups according to the symptoms declared by the patients.

Conclusion

Our results suggest that the analytical methodology used and the threshold for lactose breath tests should be reconsidered, especially in view of the extreme variability known to affect intestinal microbiome, a condition that can greatly affect the diagnostic outcome. Taking into account previous studies, indicating a significant underestimation of lactase genetic nonpersistence when using H2/CH4 standard breath tests,11 our results can contribute to the discussion on the subject that has relevant consequences on lactose malabsorption diagnosis that might be missed.

Availability of data and materials

The data that support the findings of this study are available from Data Medica Group, Padova, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Data Medica Group, Padova.

Acknowledgment

We thank the laboratory staff in Data Medica for helping with data collection, in particular Dr Giovanni Lenzo and Dr Alessia Caltabiano.

Disclosure

The authors report no conflicts of interest in this work.

References

1.

Tomba C, Baldassarri A, Coletta M, Cesana BM, Basilisco G. Is the subjective perception of lactose intolerance influenced by the psychological profile? Aliment Pharmacol Ther. 2012;36(7):660–669.

2.

Deng Y, Misselwitz B, Dai N, Fox M. Lactose intolerance in adults: biological mechanism and dietary management. Nutrients. 2015;7(9):8020–8035.

3.

Casellas F, Aparici A, Pérez MJ, Rodríguez P. Perception of lactose intolerance impairs health-related quality of life. Eur J Clin Nutr. 2016;70(9):1068–1072.

4.

Lomer MCE, Parkes GC, Sanderson JD. Review article: lactose intolerance in clinical practice – myths and realities. Aliment Pharmacol Ther. 2008;27(2):93–103.

5.

Zheng X, Chu H, Cong Y, et al. Self-reported lactose intolerance in clinic patients with functional gastrointestinal symptoms: prevalence, risk factors, and impact on food choices. Neurogastroenterol Motil. 2015;27(8):1138–1146.

6.

Dzialanski Z, Barany M, Engfeldt P, Magnuson A, Olsson LA, Nilsson TK. Lactase persistence versus lactose intolerance: is there an intermediate phenotype? Clin Biochem. 2016;49(3):248–252.

7.

Simrén M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55(3):297–303.

8.

Rosado JL, Solomons NW. Sensitivity and specificity of the hydrogen breath-analysis test for detecting malabsorption of physiological doses of lactose. Clin Chem. 1983;29(3):545–548.

9.

Furnari M, Bonfanti D, Parodi A, et al. A comparison between lactose breath test and quick test on duodenal biopsies for diagnosing lactase deficiency in patients with self-reported lactose intolerance. J Clin Gastroenterol. 2013;47(2):148–152.

10.

Houben E, de Preter V, Billen J, Ranst MA, Verbeke K. Additional value of CH4 measurement in a combined 13C/H2 lactose malabsorption breath test: a retrospective analysis. Nutrients. 2015;7(9):7469–7485.

11.

Enko D, Rezanka E, Stolba R, Halwachs-Baumann G. Lactose malabsorption testing in daily clinical practice: a critical retrospective analysis and comparison of the hydrogen/methane breath test and genetic test (C/T-13910 polymorphism) results. Gastroenterol Res Pract. 2014;2014:1–6.

12.

Sidiqui I, Ahmed S, Abid S. Update on diagnostic value of breath test in gastrointestinal and liver diseases. World J Gastrointest Pathophysiol. 2016;7(3):256–265.

13.

Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775–784.

14.

Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment Pharmacol Ther. 2009;29(Suppl 1):1–3.

15.

Hovde Ø, Farup PG. A comparison of diagnostic tests for lactose malabsorption – which one is the best? BMC Gastroenterol. 2009;9:82–88.

16.

Di Rienzo T, D’Angelo G, D’Aversa S, et al. Lactose intolerance: from diagnosis to correct management. Eur Rev Med Pharmacol Sci. 2013;17(Suppl 2):18–25.

17.

Satta PU, Scarpa M, Oppia F, Cabras F. World lactose malabsorption and intolerance: what should be the best clinical management? World J Gastrointest Pharmacol Ther. 2012;3(3):29–33.

18.

Krawczyk M, Wolska M, Schwartz S, et al. Concordance of genetic and breath tests for lactose intolerance in a tertiary referral centre. J Gastrointest Liver Dis. 2008;17:135–139.

19.

Storhaug CL, Fosse SK, Fadnes LT. Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(10):738–746.

20.

Zadro C, Dipresa S, Zorzetti G, Pediroda A, Menegoni F. Lactase non-persistent genotype distribution in Italy. Minerva Gastroenterol Dietol. 2017;63(3):264–269.

Creative Commons License © 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.